|
|
Profile
|
Delegates :
Dr. Tetsu ARISAWA, CEO |
|
Incorporated :
September 13 , 2019 |
Paid in Capital :
5 Million yen |
Employees :
人 |
Address :
P202,3-9,fukuura,Kanazawa-ku,Yokohama-city KANAGAWA
〒236-0004
|
TEL/FAX :
045-353-5302 / |
URL：
https://ampametry.com/en |
Attachment :
|
Mission/Background :
Ampametry is a startup company originating from the Department of Physiology, Yokohama City University established Sep. 13th, 2019. We have developed the world’s first AMPA-Positron Emission Tomography (PET) technology that can image and quantify the distribution of AMPA-type receptors in the brain in vivo.
AMPA (receptor) + metry (measure) = Ampametry
It is our mission at Ampametry to spread this technology across the world and to pioneer novel neuropsychiatric research, diagnosis, and treatment. |
|
Technology & Business
|
<Contract research for clinical and non-clinical studies using AMPA-PET>
We support the discovery of new neuropsychiatric drugs with AMPA-PET technology.
AMPA receptors are thought to be associated with many neuropsychiatric disorders, although only a few drugs target AMPA receptors. With AMPA-PET, changes in AMPA receptors in the brain can be detected; hence, it is possible to select target patients and evaluate drug efficacy, and to conduct clinical development of drugs efficiently and effectively.
We have already performed AMPA-PET imaging and image analysis of many cases. Please contact us if you would like to consider a clinical trial using AMPA-PET.
AMPA-PET can be used to track changes in AMPA receptors, even in preclinical studies using a PET camera for small animals. With AMPA-PET, it is also possible to observe changes over time using the same object/individual. Please contact us if you are interested.
|
|
Products & Service
|
Products & Service Name
|
Stage
|
Outline
|
Milestone
|
Equipment for manufacturing and synthesizing AMPA-PET drugs (medical device)
|
Phase3
|
Equipment for synthesizing AMPA-PET drugs ([^11C]K-2) is available for institutions performing brain PET imaging.
|
Completion of clinical trials to obtain manufacturing and marketing authorisation as a medical device.
|
AMPA-PET drugs (Radiopharmaceuticals)
|
Phase2
|
PET agent that can image AMPA receptors, "[^11C]K-2".
|
Preparation of clinical trials for approval
|
Software for AI diagnosis and analysis of AMPA-PET images (SaMD)
|
NDA filed
|
Instant analysis of AMPA-PET images, showing values that contribute to the appraisal of depression or bipolar disorder.
|
Establishment of a QMS system for application for approval.
|
Contract Research Services
|
Launched
|
Evaluation of drug efficacy of central nervous system medicines with the PET drug "[^11C]K-2".
|
Searching for domestic and foreign pharmaceutical companies, research institutions and other request sources.
|
Technology alliances, joint research using proprietary technologies
|
Launched
|
Drug discovery applications include AMPA receptor, drug efficacy evaluation with AMPA-PET, and target disease selection.
|
Searching for partners, including national and international pharmaceutical companies and research institutions
|
|
Highlights
|
A new paper by our director, Prof. Takuya Takahashi of Yokohama City University, has been published in the online edition of Molecular Psychiatry (https://www.nature.com/articles/s41380-024-02785-1). This study reveals AMPA receptor variations in the brains of patients with psychiatric disorders, marking a world-first discovery in these conditions and reinforcing the utility of AMPA-PET in evaluating psychiatric and neurological disorders.
|
|
Alliance strategy
|
We seek partners for licensing or contract research using our AMPA-PET technology, including pharmaceutical companies or universities focused on CNS and psychiatric disease research.
Our AMPA-PET technology, the first to image and quantify AMPA receptor distribution in the human brain, uses the PET agent “[11C]K-2.” As the first tool worldwide to visualize AMPA receptors, it shows promise for neurological and psychiatric disease diagnosis, drug development, and aiding in understanding pathophysiology.
|
|
|